Charles River Laboratories
For 2005, revenue was up 46.3% to $1.1 billion, while per-share earnings rose 16.7% to $1.96. Fourth-quarter revenue increased 22.3%, while EPS climbed 115.6% to $0.69. The gains in GAAP EPS were inflated, though, because of several charges; taking into account these items, non-GAAP full-year EPS increased 15.7% and fourth-quarter EPS increased 22.9%.
Charles River has three operating segments -- Research Models and Services, Preclinical Services, and Clinical Services. Preclinical Services has been the growth engine of late, as sales rose 40% year over year in the fourth quarter, although that performance had a lot to do with the company's acquisition of Inveresk in 2004.
Still, Charles River is expecting that preclinical demand will continue to be robust, and it's preparing to meet that demand. This is where the risk comes in. The firm plans to incur between $175 million and $200 million in capital expenditures in 2006 -- up from $96.7 million in 200 -- as it builds out its preclinical capacity.
Charles River is reportedly seeing more activity from biotech outfits, in addition to existing business from larger pharmaceutical names like Eli Lilly
Charles River is in no immediate danger; on the contrary, demand for its products appears reasonably strong. Backlog for its preclinical and clinical business reached $448.2 million in the fourth quarter, an increase of $17.1 million from the third quarter. Still, the company is embarking on a pretty big expansion. Investors would do well to closely monitor backlog and performance in the preclinical business in the coming quarters.
For more on Charles River:
Fool contributor Brian Gorman is a freelance writer in Chicago. He does not own shares of any companies mentioned in this article.